Robotics can support surgery, caregiving, and care at home, helping address labor shortages while improving access and experience. Across many of these ‘hot spots’, AI is playing a crucial role in helping to reshape where value can exist in 2026. The common thread across RCM, diagnostics, CROs, QMS, or tools is the same – AI is often the underlying driver of efficiency – compressing labor costs, changing how workflows scale, and eroding moats built on manual processes or point solutions. For deeper insights into the market, and more from Tommy Erdei and the Jefferies team, check out the 2024 Healthcare Temperature Check and follow coverage of this year’s Global Healthcare Conference.
Over a billion people living with mental health conditions – services require urgent scale-up
However, energy efficiency varies wildly between models, with the least efficient inference consuming over 10 times more power than the most efficient, highlighting the growing environmental concerns around AI deployment. IEEE Spectrum’s comprehensive analysis reveals that AI models are rapidly conquering benchmarks but still struggle with surprisingly basic tasks like reading analog clocks. While multimodal LLMs are advancing at breakneck speed, even top models like OpenAI’s GPT-5.4 only achieve 50% accuracy on clock-reading tasks, with Anthropic’s Claude Opus 4.6 managing just 8.9% accuracy.
- Total deal value saw a major increase of 549.8 percent to $20.8 billion, reflecting a shift toward larger corporate and strategic acquisitions.
- Explore options that provide exposure to defensive growth sectors amid rising cyber threats.
- This performance was underpinned by 11 megadeals (transactions valued greater than $5bn), up from three in 2024.
- The common thread across RCM, diagnostics, CROs, QMS, or tools is the same – AI is often the underlying driver of efficiency – compressing labor costs, changing how workflows scale, and eroding moats built on manual processes or point solutions.
- In addition, buyers are increasingly attracted to companies as potential M&A targets that are differentiated by emerging platform capabilities such as AI-enabled trial design, modern imaging modalities, real-world-evidence integration, and autonomous safety workflows.
Top deals
EY-Parthenon is a brand under which a number of EY member firms across the globe provide strategy consulting services. While inpatient volume growth has been modest, higher acuity has resulted in sustained utilization. Many large AMCs have exceeded the 80%–85% bed utilization threshold commonly used for https://www.onlegalresources.com/exploring-careers-at-a-pharmacy-opportunities-and-roles.html strategic planning. Healthcare leaders have key growth opportunities in 2026 despite the mounting pressures that are reshaping the industry. Buyers must assess how targets align with risk-bearing models, especially in primary care, behavioral health, and chronic care management. So I think there’s a lot of innovation that has the potential to transform our industry.
Join our mailing list to see future posts
Medtech acquirers are prioritising targets that bring not only differentiated technology but also the data, software and service layers that support recurring revenue and stronger customer retention. Financial investors are highly active, particularly in corporate carveouts, where operational efficiencies and technology enablement can unlock additional value. Many of these assets offer strong fundamentals, but greater autonomy enables clearer strategy and more targeted investment, allowing them to reach their full potential.
Meta Plans to Open Source New AI Models as Company Struggles with User Adoption
Since 1999, we’ve been a leading provider of financial technology, and our clients turn to us for the solutions they need when planning for their most important goals. Enabled by data and technology, our services https://www.ourbow.com/healthwatch-wants-to-hear-from-you/ and solutions provide trust through assurance and help clients transform, grow and operate. In the life sciences space, after several years of elevated investment volume, activity has finally simmered back down to pre-pandemic levels. There were only two life sciences deals in 2024 that exceeded $5B (for comparison, there were nine that exceeded that threshold in 2023).
Provider Services and Technology Integration
- Many have updated their policies, adopted rights-based approaches, and enhanced preparedness for mental health and psychosocial support during health emergencies.
- Our research for this report examined key trends, opportunities, and risks for investors across HCLS.
- Looking ahead, investors will need conviction in their value-creation playbooks to deliver outsized returns as competition for assets remains intense.
- Seventy-six percent responded that they expected more deals in the year ahead than in 2024, with 43 percent predicting deal volume would grow by at least 10 percent.
- These trends might seem surprising at first glance, given that the general industry commentary suggests that provider margins finally started to stabilize in 2023, and improved even further across 2024.
- We also expect payers to reenter the investment landscape as operating pressures ease and they refocus on technology enabled growth.
And new efforts to generate power for AI in a way that avoids network charges could help avoid power grid constraints. The global economy and financial markets are being transformed by mega forces – big structural shifts like the low-carbon transition or demographic divergence. With a few mega forces driving markets, it is hard to avoid making a big call on their direction – and as such, there is no neutral stance, not even exposure to broad indexes.